Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A study using data from the China Kadoorie Biobank study (CKB) and led by researchers from Oxford Population Health and Peking University has found that gout is linked to increased risk of several diseases.

Patients in China are waiting outside

Gout is the most common form of inflammatory arthritis. The study, published today in The Lancet Regional Health – Western Pacific, provides a comprehensive assessment of the distribution pattern of gout and hyperuricemia (the sustained elevated blood urate level, a measure of the amount of uric acid in the blood and a precursor of gout) and their relationships with a range of other diseases in a Chinese population. The findings may inform prevention and management approaches in China and globally.

The researchers analysed data from 0.5 million CKB participants recruited between 2004 and 2008 from ten diverse urban and rural areas in China. All participants had comprehensive baseline self-reported information on lifestyle risk factors and medical history and were followed up for 12 years with linked electronic health records, with 16,800 participants also having blood plasma urate level measured.

The researchers examined how common gout and hyperuricemia were in difference socio-demographic subgroups, and then looked at the relationships between gout and 16 major conditions and death from all causes.

 

Read the full story on the Nuffield Department of Population Health website.

Similar stories

University of Oxford and Serum Institute of India agree licence to advance the next-generation multi-stage malaria vaccine candidate component

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.